EGFR-antagonistic affibody-functionalized Pt-based nanozyme for enhanced tumor radiotherapy
Source abstract
Abstract
Clinical radiotherapy (RT) is severely limited by hypoxic tumor microenvironment and a lack of targeting precision. Therefore, it is crucial to develop highly efficient radiosensitizers to enhance RT efficacy. Herein, a novel kind of epidermal growth factor receptor (EGFR)-antagonistic affibody-functionalized Pt-based nanozyme for RT sensitization to EGFR-positive tumors was developed. In this study, porous platinum nanoparticles (pPt NPs) featuring catalase (CAT)-like activity and strong radiation energy absorption ability were first synthesized. Then, a thin biomimetic polydopamine (PDA) layer was coated on pPt NPs to optimize its biocompatibility as well as provide a reactive surface. Finally, a dimeric EGFR-antagonistic affibody called ZEGFR expressed by the Escherichia coli (E. coli), was conjugated to pPt@PDA NPs (termed pPt@PDA-ZEGFR NPs) to precisely recognize EGFR-positive A431 tumors. Under the navigation of ZEGFR, superior tumor homing was achieved with these Pt-based nanozymes, which was ascribed to EGFR receptor-mediated endocytosis. As high-Z metal NPs exhibit an inherently strong ability to absorb radiation energy and catalyze endogenous H2O2 in tumors, the pPt@PDA-ZEGFR NPs demonstrated superb therapeutic efficacy; specifically, the NPs significantly inhibited HIF-1α expression and increased RT-induced DNA damage. Furthermore, the biosafety of these Pt-based nanozymes was good during short-term treatment. In summary, EGFR-antagonistic affibody-functionalized Pt-based nanozymes are promising radiosensitizers for the precise therapy of EGFR-positive tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (72)
Show source-provided references
1. Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection10.1039/D1CS01145F ↗
2. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy10.1073/pnas.030545097 ↗
3. FLASH radiotherapy: current knowledge and future insights using proton-beam therapy10.3390/ijms21186492 ↗
4. Induction of cell death by radiotherapy10.1677/erc.0.0060041 ↗
5. Scaling parameter of the lethal effect of mammalian cells based on radiation-induced OH radicals: effectiveness of direct action in radiation therapy10.1093/jrr/rraa111 ↗
6. Radiotherapy combination opportunities leveraging immunity for the next oncology practice
7. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers10.1038/bjc.2011.240 ↗
8. Exploiting tumour hypoxia in cancer treatment
9. Microenvironment and radiation therapy10.1155/2013/685308 ↗
10. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence10.1038/nrc3958 ↗
11. Fluorinated hyaluronic acid encapsulated perfluorocarbon nanoparticles as tumor-targeted oxygen carriers to enhance radiotherapy10.1021/acs.molpharmaceut.2c00432 ↗
12. Coordination polymer-coated CaCO3 reinforces radiotherapy by reprogramming the immunosuppressive metabolic microenvironment10.1002/adma.202106520 ↗
13. Erythrocyte-Membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy10.1002/adma.201701429 ↗
14. An oxygen-enriched thermosensitive hydrogel for the relief of a hypoxic tumor microenvironment and enhancement of radiotherapy10.1039/D1BM01280K ↗
15. In vitro macrophage uptake and in vivo biodistribution of PLA–PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content10.1007/s10856-009-3746-9 ↗
16. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance10.1016/j.biomaterials.2018.08.004 ↗
17. Au–Hemoglobin loaded platelet alleviating tumor hypoxia and enhancing the radiotherapy effect with low-dose X-ray10.1021/acsnano.0c06541 ↗
18. Nanozymes: classification, catalytic mechanisms, activity regulation, and applications10.1021/acs.chemrev.8b00672 ↗
19. Structure and activity of nanozymes: inspirations for de novo design of nanozymes10.1016/j.mattod.2020.08.020 ↗
20. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles10.1038/nnano.2007.260 ↗
21. Biodegradable two-dimensional nanomaterials for cancer theranostics10.1016/j.ccr.2022.214415 ↗
22. Multifunctional MnO2 nanoparticles for tumor microenvironment modulation and cancer therapy10.1002/wnan.1720 ↗
23. Simultaneous Fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy10.1002/ange.201712027 ↗
24. Manganese-based hollow nanoplatforms for MR imaging-guided cancer therapies10.1186/s40824-022-00275-5 ↗
25. Biomimetic hybrid nanozymes with self-supplied H+ and accelerated O2 generation for enhanced starvation and photodynamic therapy against hypoxic tumors10.1021/acs.nanolett.9b00934 ↗
26. A mesoporous nanoenzyme derived from metal–organic frameworks with endogenous oxygen generation to alleviate tumor hypoxia for significantly enhanced photodynamic therapy10.1002/adma.201901893 ↗
27. Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy10.1186/s12951-021-00885-6 ↗
28. Radiotherapy enhancement with gold nanoparticles10.1211/jpp.60.8.0005 ↗
29. Emerging nanotechnology and advanced materials for cancer radiation therapy10.1002/adma.201700996 ↗
30. Engineering gold-based radiosensitizers for cancer radiotherapy10.1039/C7MH00451F ↗
31. A pH-responsive Pt-based nanoradiosensitizer for enhanced radiotherapy via oxidative stress amplification10.1039/D1NR02043A ↗
32. Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo10.1016/j.biomaterials.2019.01.004 ↗
33. Principles of cancer treatment by radiotherapy
34. Multidisciplinary strategies to enhance therapeutic effects of flavonoids from Epimedii Folium: integration of herbal medicine, enzyme engineering, and nanotechnology10.1016/j.jpha.2022.12.001 ↗
35. Ligand-targeted theranostic nanomedicines against cancer10.1016/j.jconrel.2016.01.002 ↗
36. Engineering folate–drug conjugates to target cancer: from chemistry to clinic10.1021/bc2005522 ↗
37. Radiolabelled RGD peptides for imaging and therapy10.1007/s00259-011-2028-1 ↗
38. Immunoconjugates for cancer targeting: a review of antibody-drug conjugates and antibody-functionalized nanoparticles10.2174/0929867327666200525161359 ↗
39. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors10.1016/j.ijpharm.2016.03.060 ↗
40. Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors10.1016/j.ijpharm.2022.121609 ↗
41. In vitro-engineered non-antibody protein therapeutics10.1007/s13238-017-0386-6 ↗
42. Preclinical and clinical safety of monoclonal antibodies, Drug Discov
43. Update: affibody molecules for molecular imaging and therapy for cancer
44. Development of HER2-targeting-ligand-modified albumin nanoparticles based on the SpyTag/SpyCatcher system for photothermal therapy10.1021/acs.biomac.1c00336 ↗
45. Affibody-attached hyperbranched conjugated polyelectrolyte for targeted fluorescence imaging of HER2-positive cancer cell10.1021/bm200563a ↗
46. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer10.1093/annonc/mdh011 ↗
47. TRAIL & EGFR affibody dual-display on a protein nanoparticle synergistically suppresses tumor growth10.1016/j.jconrel.2022.07.004 ↗
48. Antitumour immunity regulated by aberrant ERBB family signalling10.1038/s41568-020-00322-0 ↗
49. Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors10.1016/j.ijpharm.2022.121746 ↗
50. Improved discrimination of tumors with low and heterogeneous EGFR expression in fluorescence-guided surgery through paired-agent protocols
51. Identification of a suitable untargeted agent for the clinical translation of ABY-029 paired-agent imaging in fluorescence-guided surgery
52. Intraoperative detection of micrometastases in whole excised lymph nodes using fluorescent paired-agent imaging principles: identification of a suitable staining and rinsing protocol10.1007/s11307-021-01587-z ↗
53. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models10.1016/j.ijpharm.2020.119541 ↗
54. Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers10.1021/nn405809c ↗
55. Porous Pt nanoparticles loaded with doxorubicin to enable synergistic Chemo-/Electrodynamic Therapy10.1016/j.biomaterials.2020.120202 ↗
56. Combining photothermal therapy and immunotherapy against melanoma by polydopamine-coated Al2O3 nanoparticles10.7150/thno.24073 ↗
57. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance10.1593/neo.10688 ↗
58. Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity10.1016/j.biomaterials.2020.120159 ↗
59. Radiotherapy combined with immunotherapy: the dawn of cancer treatment10.1038/s41392-022-01102-y ↗
60. γH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization10.4161/cc.9.4.10764 ↗
61. A polydopamine-coated platinum nanoplatform for tumor-targeted photothermal ablation and migration inhibition10.3389/fonc.2022.860718 ↗
62. Expanding global access to radiotherapy10.1016/S1470-2045(15)00222-3 ↗
63. Recent developments in radiotherapy10.1056/NEJMra1608986 ↗
64. Hypoxia as a biomarker for radioresistant cancer stem cells10.3109/09553002.2014.916841 ↗
65. Ligand-targeted therapeutics in anticancer therapy10.1038/nrc903 ↗
66. Ligand-targeted drug delivery10.1021/acs.chemrev.7b00013 ↗
67. Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy10.1002/elsc.202000027 ↗
68. Anti-EGFR therapies in nasopharyngeal carcinoma10.1016/j.biopha.2020.110649 ↗
69. Anti-EGFR antibody conjugated thiol chitosan-layered gold nanoshells for dual-modal imaging-guided cancer combination therapy10.1016/j.jconrel.2019.08.007 ↗
70. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors10.1002/cncr.22402 ↗
71. A versatile Pt-Ce6 nanoplatform as catalase nanozyme and NIR-II photothermal agent for enhanced PDT/PTT tumor therapy10.1007/s40843-020-1431-5 ↗
72. Porous Au@Pt nanoparticles: therapeutic platform for tumor chemo-photothermal Co-therapy and alleviating doxorubicin-induced oxidative damage10.1021/acsami.7b14705 ↗